<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456766</url>
  </required_header>
  <id_info>
    <org_study_id>TG1310FT</org_study_id>
    <nct_id>NCT02456766</nct_id>
  </id_info>
  <brief_title>Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for Diagnosis of Hepatic Steatosis</brief_title>
  <official_title>A Multicenter Clinical Study on the Comparison of Acoustic Attenuation Parameter Using FibroTouch With Liver Biopsy for the Diagnosis of Hepatic Steatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wuxi Hisky Medical Technology Co Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangzhou First People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>No.85 Hospital, Changning, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Hospital of Nanjing Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sichuan Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Second People's Hospital of Hangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Wuxi Hisky Medical Technology Co Ltd</source>
  <brief_summary>
    <textblock>
      This will be a multi-center, prospective, controlled study. It is expected that about 240&#xD;
      subjects from 10 study centers will be enrolled, and 224 effective subjects will be&#xD;
      statistically analyzed in the end, in which 56 effective subjects with stage F0 (25%), 56&#xD;
      effective subjects with stage F1 (25%), 56 effective subjects with stage F2 (25%), 56&#xD;
      effective subjects with stage F3 (25%). By comparison of the result of FibroTouch examination&#xD;
      with that of liver biopsy, their specificities, sensitivities and accuracies for diagnosis of&#xD;
      liver steatosis will be identified.&#xD;
&#xD;
      The patients with liver diseases who need to have a liver biopsy in hospital and meet all of&#xD;
      the inclusion criteria and none of the exclusion criteria, may participate in this study.&#xD;
      Within two weeks of FibroTouch examination, subjects are required to have qualified&#xD;
      histological specimens of liver biopsy for comparation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The coincidence for diagnosis of hepatic steatosis between fat attenuation parameter (FAP) of FibroTouch and liver biopsy by ROC analysis</measure>
    <time_frame>Within two weeks of FibroTouch examination</time_frame>
    <description>Performance of fat attenuation parameter (FAP, dB/m) of FibroTouch will be assessed using ROC analysis for the detection of hepatic steatosis stage F0 (&lt;5%), stage F1 (5%-33%), stage F2 (34%-66%), and stage F3 (2&gt;66%) using liver biopsy as the reference.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Hepatic Steatosis</condition>
  <condition>Liver Steatosis</condition>
  <arm_group>
    <arm_group_label>F0</arm_group_label>
    <description>Liver Steatosis Grade: &lt;5%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F1</arm_group_label>
    <description>Liver Steatosis Grade: 5-33%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F2</arm_group_label>
    <description>Liver Steatosis Grade: 34-66%</description>
  </arm_group>
  <arm_group>
    <arm_group_label>F3</arm_group_label>
    <description>Liver Steatosis Grade: &gt; 66%</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FibroTouch</intervention_name>
    <arm_group_label>F0</arm_group_label>
    <arm_group_label>F1</arm_group_label>
    <arm_group_label>F2</arm_group_label>
    <arm_group_label>F3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Liver Biopsy</intervention_name>
    <arm_group_label>F0</arm_group_label>
    <arm_group_label>F1</arm_group_label>
    <arm_group_label>F2</arm_group_label>
    <arm_group_label>F3</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Liver Biospy Specimens&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The subjects with liver diseases who need to have a liver biopsy in hospital and meet all&#xD;
        of the inclusion criteria and none of the exclusion criteria, may participate in this&#xD;
        study. Within two weeks of FibroTouch examination, subjects are required to have qualified&#xD;
        histological specimens of liver biopsy for comparation.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject at the age of 18 to 65 years, non-limited gender.&#xD;
&#xD;
          -  Within two weeks of FibroTouch examination, qualified histological specimens of liver&#xD;
             biopsy are required. Using the liver biopsy needle of 16G or 14CT, puncture and remove&#xD;
             more than 2.0 centimeters long liver tissue (including at least 11 portal areas, no&#xD;
             less than 6 complete portal areas and the minimum length of specimen should be more&#xD;
             than 1.0 centimeter).&#xD;
&#xD;
          -  Willing and able to abide by all principles and complete all study procedures.&#xD;
&#xD;
          -  Willing and can provide written informed consent form by patient or patient's legal&#xD;
             guardian.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject with active or suspected cancer or history of malignant tumor by evidence&#xD;
             within 5 years before enrolling. And the subject who has the liver malignant tumors&#xD;
             injury cannot participate in this study.&#xD;
&#xD;
          -  There is evidence that the subject has a history of alcohol overdoses* or drug abuse.&#xD;
             Definition of alcohol overdoses: 40 gram (g)/day for male and 40 g/day for female.&#xD;
             Alcohol intake (g) = the volume of drinking (ml) × alcohol percentage (%, v/v) × 0.8&#xD;
             (g/ml); 1g alcohol is the equal of 25-40 ml of beer, 8-10ml of Chinese rice wine,&#xD;
             5-12ml of (grape) wine, 3-7ml of health care liquor or Chinese spirits.&#xD;
&#xD;
          -  Subject with alcoholic liver disease and hepatitis C.&#xD;
&#xD;
          -  Pregnant or nursing woman, and subject with a pregnant plan and is unwilling to take&#xD;
             contraceptive measures during this study.&#xD;
&#xD;
          -  Subject with history of organ transplantation or has functional grafts (except for the&#xD;
             cornea or hair graft).&#xD;
&#xD;
          -  Subject with non-healing wound on the right upper abdomen at this moment.&#xD;
&#xD;
          -  In the investigator's opinion, the subject is unsuitable to participate in the study&#xD;
             as he or she has a history of serious illness, or other evidence shown that the&#xD;
             subject has any other serious illness.&#xD;
&#xD;
          -  Subject who participates in other clinical trial at the same time.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lungen LU, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng LU, Bachelor</last_name>
    <phone>+86-10-62701872</phone>
    <email>lupeng@fibrotouch.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo WANG, Bachelor</last_name>
    <phone>+86-10-62701872</phone>
    <email>wangbo@fibrotouch.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sichuan Academy of Medical Sciences &amp;Sichuan Provincial People's Hospital</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liangping LI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Guangzhou First Municipal People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjian ZHOU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second People's Hospital of Hangzhou</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junping SHI, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital Of Nanjing</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongfeng YANG, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qing XIE, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai 85 Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Qingchun FU, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai First People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lungen LU, MD</last_name>
      <email>lungenlu1965@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiangao FAN, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>March 22, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FibroTouch</keyword>
  <keyword>acoustic attenuation parameter</keyword>
  <keyword>liver biopsy</keyword>
  <keyword>hepatic steatosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

